Triamcinolone (When ATH D07AB09)

When ATH:
D07AB09

Characteristic.

White or white with a yellow tinge crystalline powder. Insoluble in water, poorly soluble in alcohol.

Pharmacological action.
Glucocorticoid, anti-inflammatory, antiallergic, immunosuppressive.

Application.

Adrenal insufficiency, autoimmune thyroiditis, hypercalcemia of malignancy, psoriaticheskiy arthritis, gout and rheumatoid arthritis (including juvenile), ankiloziruyushtiy spondylitis, ʙursit, tendinitis, posttravmaticheskiy osteoarthritis, epicondylitis, systemic lupus erythematosus, revmokardit, pemphigus, Syndrome Stevens - Johnson, erythema multiforme, dermatitis (exfoliative, herpetiform, bullous, seborrheal, contact, atonic), psoriasis, nasal allergy, bronchial asthma, serum or disease drug, allergic conjunctivitis, keratit, iridocyclitis, sarkoidoz, Loffler's syndrome, ʙorrelioz, inhalation pneumonia, adult idiopathic thrombocytopenic purpura, adult secondary thrombocytopenia, anemia (autoimmune hemolytic, hereditary hypoplastic), erythroblastopenia, acute or chronic lymphocytic leukemia, limfogranulematoz, non-Hodgkin's lymphoma, mammary cancer, prostate cancer, multiple myeloma, tuberculous meningitis, acute lymphocytic leukemia in children, nephrotic syndrome, nespetsificheskiy yazvennыy colitis, Crohn's disease, celiac disease, hyperthermia in malignant tumors.

Contraindications.

Hypersensitivity, systemic mycosis, glaucoma, gastric ulcer and duodenal ulcer, violation of kidney function, osteoporosis, acute viral and bacterial infections, pregnancy, lactation, Children up to age 6 years.

Side effects.

Insomnia, anxiety, withdrawal (adrenal insufficiency), secondary immunodeficiency (exacerbation of chronic infectious diseases, generalization of infectious process, opportunistic infections), slowing of reparative processes, steroid diabetes, the syndrome itsenko-Kushinga, arterial hypertension, myocardial dystrophy, cardiac arrhythmias, swelling, muscular weakness, amyotrophy, osteoporosis, multiple caries, spontaneous fractures, growth retardation in children, steroid stomach ulcers, bowel atony, tendency to thrombosis, atrophy of the skin at the site of application, hypertryhoz, striae, folliculitis, maceration or dryness of the skin, allergic reactions.

Cooperation.

Reduces the effectiveness of oral hypoglycemic agents, insulin, antihypertensive and diuretic drugs, somatotropin. When combined with viral vaccines promotes replication of virus particles and / or reduce antibody production. Enhances the side effects of NSAIDs, cytostatics and immunosuppressants.

Overdose.

Symptoms: the syndrome itsenko-Kushinga, giperglikemiâ, glycosuria, skin irritation at the site of application, itch, burning.

Treatment: maintaining vital functions (against the background of the gradual withdrawal of the drug).

Dosing and Administration.

Inside, after meal. Adults and adolescents (senior 12 years) in case of insufficiency of the adrenal cortex is 4-12 mg per day once (morning) or in 2 admission (morning and afternoon). When other states: 4-48 mg per day once or 2 admission. / M is 40-80 mg, if necessary, repeated at 4 Sun. In the joint cavity or vagina tendon -2.5-15 mg repetitive injections as needed. Children from 6 to 12 years with adrenal insufficiency: 0,117 mg/kg once in the morning or 2 admission, in other cases — 0.416-1.7 mg/kg; the maximum daily dose for children weighing up to 25 kg-12-14 mg. V/m is 40 mg with repetition through injections 4 weeks as needed or 0.03-0.2 mg/kg (again after 1-7 days).

Cooperation